X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com//news-release/2023/12/15/2797283/0/en/Aridis-Pharmaceuticals-Announces-Adjournment-of-Annual-Meeting-of-Stockholders-until-January-12-2024.html
https://www.globenewswire.com//news-release/2023/11/03/2773449/0/en/Aridis-Pharmaceuticals-Announces-Third-Quarter-2023-Financial-Results-and-Business-Update.html
https://www.globenewswire.com/news-release/2023/08/02/2716835/0/en/Aridis-Pharmaceuticals-Announces-2-Million-Offering.html
https://endpts.com/aridis-to-delist-from-nasdaq-bicycle-closes-200m-offering/
https://www.globenewswire.com/news-release/2023/07/17/2705972/0/en/Aridis-Receives-Agreement-from-the-European-Medicines-Agency-EMA-on-the-Clinical-Study-Design-and-a-Single-Confirmatory-Phase-3-Study-of-AR-301.html
https://www.marketwatch.com/story/aridis-pharma-shares-rise-33-after-fda-product-designation-for-ar-301-871e724c#:~:text=Aridis%20Pharmaceuticals%20shares%20were%20up,pneumonia%20caused%20by%20gram%2Dpositive
https://www.globenewswire.com/news-release/2023/07/12/2703466/0/en/Aridis-AR-301-Monoclonal-Antibody-is-Among-the-First-Biologics-to-Receive-FDA-s-Qualified-Infectious-Diseases-Product-QIDP-Designation.html
https://www.globenewswire.com/news-release/2023/06/20/2691027/0/en/Aridis-Pharmaceuticals-AR-301-Eligible-for-Consideration-under-FDA-s-Limited-Population-Pathway-for-Antibacterial-and-Antifungal-Drugs-LPAD.html
https://www.globenewswire.com/news-release/2023/05/31/2679348/0/en/Aridis-Receives-Agreement-from-the-FDA-on-a-Single-Confirmatory-Phase-3-Study-of-AR-301-and-the-Clinical-Study-Design.html
https://www.globenewswire.com/news-release/2023/05/25/2676708/0/en/Aridis-Pharmaceuticals-Receives-Nasdaq-Notice-on-Late-Filing-of-its-Form-10-Q.html
Market Place
Share 
